Selected Publication:
SHR
Neuro
Cancer
Cardio
Lipid
Metab
Microb
Ginter-Hanselmayer, G; Smolle, J; Gupta, A.
Itraconazole in the treatment of tinea capitis caused by Microsporum canis: experience in a large cohort.
PEDIAT DERMATOL. 2004; 21(4): 499-502.
Doi: 10.1111/j.0736-8046.2004.21419.x
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Leading authors Med Uni Graz
-
Ginter-Hanselmayer Gabriele
- Co-authors Med Uni Graz
-
Smolle Josef
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Mycotic scalp infection caused by Microsporum canis is one of the more recalcitrant disorders, with increasing incidence during the last decade. We report our experience with administration of itraconazole in 163 children (86 girls, 77 boys) with M. canis tinea capitis. Fifty-five patients had previous treatment with terbinafine without success. In all children, the dosage of itraconazole was adjusted according to body weight, with 5 mg/kg/day given in a continuous regimen either as a capsule (116 patients) or an oral suspension (47 patients). In all children, there was both clinical and mycologic cure after a mean treatment period of 39 +/- 12 days (range 10-77 days). Eleven children (6.7%) had side effects: diarrhea in five children, cutaneous eruption in four, and abdominal pain in two. Itraconazole was effective and safe for the treatment of M. canis tinea capitis.
- Find related publications in this database (using NLM MeSH Indexing)
-
Administration, Oral -
-
Antifungal Agents - administration and dosage
-
Child - administration and dosage
-
Child, Preschool - administration and dosage
-
Cohort Studies - administration and dosage
-
Female - administration and dosage
-
Humans - administration and dosage
-
Infant - administration and dosage
-
Itraconazole - administration and dosage
-
Male - administration and dosage
-
Microsporum - isolation and purification
-
Prospective Studies - isolation and purification
-
Tinea Capitis - drug therapy